Anti-platelet drug useful


Patients with coronary stents require medication that inhibits platelet activity and prevents clotting. However, if patients need additional surgery that medication must be stopped several days in advance because it increases the risk of major bleeding during the operation. A new study tested an investigational drug that decreases clotting risk and also leaves the system quicker after it is stopped so surgery can be performed without a major delay. Catherine Dolf has more in this week’s JAMA Report.

Enhanced by Zemanta
This entry was posted in Antiplatelet drug, Coagulation, Coronary stent, Health, JAMA Report, Journal of the American Medical Association, Percutaneous coronary intervention, Surgery. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s